



FOI REF: 23/630

17th October 2023

Tel: 0300 131 4500
Website: www.esht.nhs.uk

FREEDOM OF INFORMATION ACT

I am responding to your request for information under the Freedom of Information Act.

[The answers to your specific questions are contained within the attached document.](#)

If I can be of any further assistance, please do not hesitate to contact me.

Should you be dissatisfied with the Trust's response to your request, you have the right to request an internal review. Please write to the Freedom of Information Department (esh-tr.foi@nhs.net), quoting the above reference, within 40 working days. The Trust is not obliged to accept an internal review after this date.

Should you still be dissatisfied with your FOI request, you have the right of complaint to the Information Commissioner at the following address:

The Information Commissioner's Office
Wycliffe House
Water Lane
Wilmslow
Cheshire SK9 5AF

Telephone: 0303 123 1113

Yours sincerely

Linda Thornhill (Mrs)
Corporate Governance Manager
esh-tr.foi@nhs.net

Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of June 2023 and end of August 2023?

Please provide data for the latest 3-month period, if Jun to Aug is not available yet

Name of medicine	Number patients treated
1.1 Abemaciclib (Verzenios)	13
1.2 Alpelisib (Piqray)	2 WITH FULVESTRANT
1.3 Fulvestrant (fulvestrant or Faslodex)	28 WITH OTHER CANCER DRUGS
1.4 Palbociclib (Ibrance)	6 WITH FULVESTRANT 29 SINGLE AGENT
1.5 Ribociclib (Kisqali)	20 WITH FULVESTRANT 29 SINGLE AGENT

Q2. How many patients received abemaciclib (Verzenios) for early breast cancer in the 3 months between the start of June 2023 and end of August 2023?

Please provide data for the latest 3-month period, if Jun to Aug is not available yet

Number patients treated
10

Q3. How many patients received abemaciclib (Verzenios) as adjuvant treatment for early breast cancer in the 3 months between the start of June 2023 and end of August 2023?

Please provide data for the latest 3-month period, if Jun to Aug is not available yet

Number patients treated
10

Q4. How many patients received abemaciclib (Verzenios) with the following treatment intent in the 3 months between the start of June 2023 and end of August 2023?

Please provide data for the latest 3-month period, if Jun to Aug is not available yet

Treatment intent	Number patients treated
4.1 Curative	0
4.2 Palliative	0
4.3 Not known / stated	13

Q5. How many patients were treated with the following medicines in combination in the 3 months between the start of June 2023 and end of August 2023?

Please provide data for the latest 3-month period, if Jun to Aug is not available yet

Name of combination or monotherapy	Number patients treated
5.1 Abemaciclib (Verzenios) + Fulvestrant (fulvestrant or Faslodex)	0
5.2 Abemaciclib (Verzenios) + an aromatase inhibitor (anastrozole, letrozole or exemestane)	7
5.3 Abemaciclib (Verzenois) + tamoxifen	1
5.4 Abemaciclib monotherapy	5
5.5 Alpelisib (Piqray) + Fulvestrant (fulvestrant or Faslodex)	2
5.6 Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex)	6
5.7 Palbociclib (Ibrance) + an aromatase inhibitor (anastrozole, letrozole or exemestane)	21
5.8 Ribociclib (Kisqali) + Fulvestrant (fulvestrant or Faslodex)	21
5.9 Ribociclib (Kisqali) + an aromatase inhibitor (anastrozole, letrozole or exemestane)	29